Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Haematological malignancies

1018 - Risen from ashes- A prospective observational study of poor prognostic multiple myeloma patients with paraplegia/ paraparesis


21 Dec 2015


Haematological malignancies


Aravindh Anand


Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526


A.S. Anand1, V.G. Kuriakose2, K.P. Resmi2, P.S. Sabarinath2

Author affiliations

  • 1 Department Of Radiotherapy & Clinical Oncology, Trivandrum Medical College, 695011 - Thiruvananthapuram (Trivandrum)/IN
  • 2 Department Of Radiotherapy And Clinical Oncology, Trivandrum Medical College, 695011 - Thiruvananthapuram (Trivandrum)/IN

Abstract 1018


To assess neurological improvement & tumour response in poor prognostic multiple myeloma patients presenting with paraplegia / paraparesis


We prospectively observed transplant ineligible myeloma patients treated from 2012-14 presenting with paraplegia / paraparesis (grade 0-2), ISS stage 2 or 3, LDH ≥1.5 times ULN. They received local RT to spine, 8 Gy / single fraction & Bortezomib/ lenalidomide/ Dexamethasone (BLD) therapy, maintenance with Lenalidomide 10 mg till progression & bisphosphonates for 2 years. The neurological parameters on presentation & disease characteristics were recorded.All the patients were reassessed weekly for neurological response and at 6 months for disease status. If patient achieved Very Good Partial Response or Complete Response were maintained on Lenalidomide. The time to any neurological response, first symptom to respond, time to motor improvement to maximum, response to pain based on analgesic use, disease progression, deaths & total follow up period were noted. The duration of symptoms & time to response / best motor grade were analyzed with Mann Whitney Cox test.


When duration of symptoms were <30 days on presentation, the mean time to any response was 2.30 weeks, time to best motor grade was 4.17 weeks, compared to 5.14 and 7.14 weeks respectively, when the duration of symptoms was > 30 days & was statistically significanct (p = 0.01 and 0.019). Median time to best motor response was 4.87 weeks with 63.3% of patients achieved grade 5 power. 86.6% achieved excellent response to BLD regimen with 23.3% CR & 63.3% VGPR.


Early initiation of local RT & BLD therapy provided best results in this subset of patients. Single 8 Gy RT gives excellent neurological response & pain relief. In myeloma, fractionated RT may not be necessary as the bone pathology is different compared to metastatic bone disease. 96.6% of the patients got total pain relief. BLD regimen produces high rates of VGPR and CR improving DFS/OS. 93.3% of patients who presented with paraplegia or just flicker of movements improved dramatically to the extent that they went back to their normal life. We conclude that even bedridden myeloma patients should always be treated with a radical intent.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings